MCID: CTN015
MIFTS: 51

Cutaneous T Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Immune diseases, Skin diseases, Blood diseases

Aliases & Classifications for Cutaneous T Cell Lymphoma

MalaCards integrated aliases for Cutaneous T Cell Lymphoma:

Name: Cutaneous T Cell Lymphoma 12 14
Lymphoma, T-Cell, Cutaneous 42 69
Cutaneous T-Cell Lymphoma 12 50
Lymphoma T-Cell Cutaneous 52
Ctcl 50

Classifications:



External Ids:

Disease Ontology 12 DOID:0060061
MeSH 42 D016410

Summaries for Cutaneous T Cell Lymphoma

NIH Rare Diseases : 50 cutaneous t-cell lymphomas (ctcls) are a group of disorders characterized by an abnormal accumulation of cancerous t-cells (a type of white blood cells) in the skin resulting in an itchy, red rash that can thicken or form a tumor. ctcls belong to a larger group of disorders known asnon-hodgkin's lymphomas. the most common types are mycosis fungoides and sézary syndrome. in some cases, cancerous t-cells may spread to the lymph nodes and eventually to other body tissues and organs, potentially resulting in life-threatening complications. the specific signs and symptoms vary from person to person. the exact cause of these conditions is unknown. last updated: 9/27/2011

MalaCards based summary : Cutaneous T Cell Lymphoma, also known as lymphoma, t-cell, cutaneous, is related to lymphoma and mycosis fungoides. An important gene associated with Cutaneous T Cell Lymphoma is CTAGE1 (Cutaneous T-Cell Lymphoma-Associated Antigen 1), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Istodax and Targretin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin's lymphoma that has material basis in a mutation of T cells.

Related Diseases for Cutaneous T Cell Lymphoma

Diseases in the Cutaneous T Cell Lymphoma family:

Primary Cutaneous Gamma/delta-Positive T-Cell Lymphoma

Diseases related to Cutaneous T Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)
id Related Disease Score Top Affiliating Genes
1 lymphoma 32.0 IFNG IL2 IL4
2 mycosis fungoides 11.6
3 parapsoriasis 11.3
4 sezary's disease 11.0
5 granulomatous slack skin disease 11.0
6 adrenal gland hyperfunction 10.6 IL15 IL2
7 bulbospinal polio 10.6 IFNG IL2
8 myoclonic astatic epilepsy 10.6 IFNG IL4
9 autoimmune polyglandular syndrome type 3 10.5 IFNG IL2
10 visual snow syndrome 10.5 IL2 IL4
11 anthracosilicosis 10.5 IFNG IL2
12 graft-versus-host disease, protection against 10.5 IFNG IL2 IL2RA
13 hemoglobin c disease 10.5 IFNA1 IL2 IL2RA
14 parametritis 10.5 IFNG IL2 IL2RA
15 cyclosporiasis 10.5 IFNG IL2 IL2RA
16 heart sarcoma 10.4 IFNA1 IFNG IL2
17 left bundle branch hemiblock 10.4 IFNG IL2 IL2RA
18 myelitis 10.4 IFNG IL2 IL2RA
19 intestinal disaccharidase deficiency 10.4 IFNG IL2 IL2RA
20 renal tubular acidosis 10.4 IFNG IL2 IL2RA
21 periodic paralysis with later-onset distal motor neuropathy 10.4 IFNG IL15
22 benign mammary dysplasia 10.4 IFNA1 IL2 IL4
23 pmm2-congenital disorder of glycosylation 10.4 IL15 IL2 IL4
24 x-linked intellectual disability, van esch type 10.3 IFNG IL2 IL4
25 eye accommodation disease 10.3 IFNG IL2RA IL4
26 lymphocytic colitis 10.3 IFNG IL2 IL4
27 tularemia 10.3 IFNG IL2 IL4
28 gonadal disease 10.3 IFNG IL2 IL4
29 hypothyroidism due to deficient transcription factors involved in pituitary development or function 10.3 IFNG IL2RA IL4
30 fibrous histiocytoma 10.3 IFNG IL2RA IL4
31 orbital osteomyelitis 10.3 IFNG IL2 IL4
32 abnormal retinal correspondence 10.3 IFNG IL2 IL4
33 legionellosis 10.3 IFNG IL2 IL4
34 opitz-kaveggia syndrome 10.3 IL2 IL4 IL7
35 erythema infectiosum 10.3 IFNG IL2 IL4
36 corneal intraepithelial neoplasm 10.3 IFNG IL2 IL4
37 acute interstitial pneumonia 10.3 IFNG IL2 IL4
38 fuchs' heterochromic uveitis 10.3 IFNG IL2 IL4
39 reardon wilson cavanagh syndrome 10.3 IFNG IL15 IL4
40 thelaziasis 10.3 IFNG IL4
41 dermatitis 10.3
42 opportunistic bacterial infectious disease 10.3 IFNG IL2 IL4
43 mucocutaneous leishmaniasis 10.2 IFNG IL2 IL4
44 acral lentiginous melanoma 10.2 IFNA1 IFNG IL2 IL2RA
45 blue toe syndrome 10.2 IFNG IL2 IL4
46 vulvar nodular hidradenoma 10.2 IFNG IL2RA IL4
47 mesenchymal cell neoplasm 10.2 IFNG IL2 IL4
48 uterus interstitial leiomyoma 10.2 IFNG IL2 IL4
49 neonatal jaundice 10.2 IFNA1 IFNG IL4
50 hyperpigmentation of eyelid 10.2 IFNG IL2 IL4

Graphical network of the top 20 diseases related to Cutaneous T Cell Lymphoma:



Diseases related to Cutaneous T Cell Lymphoma

Symptoms & Phenotypes for Cutaneous T Cell Lymphoma

MGI Mouse Phenotypes related to Cutaneous T Cell Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 IL4 IL7 TGFBR1 TIA1 TNFRSF8 ZMYND8
2 immune system MP:0005387 9.36 CCR4 HSD17B11 IFNG IL15 IL2 IL2RA

Drugs & Therapeutics for Cutaneous T Cell Lymphoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Istodax 17 46 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
2
Targretin 17 46 bexarotene VALEANT LUXEMBOURG 12/29/1999
3
UVADEX 17 METHOXSALEN Therakos February 1999
4
Valchlor 17 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013

Drugs for Cutaneous T Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 425)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 153559-49-0 82146
2
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1 298-81-7 4114
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
4
Vorinostat Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 149647-78-9 5311
5
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1 173146-27-5
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
8 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
9 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
10 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
13 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
14 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Vitamin B Complex Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
20 Histone Deacetylase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
21 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
22 Interferon-alpha Phase 4,Phase 2
23 interferons Phase 4,Phase 2,Phase 1,Early Phase 1
24 Clorazepate Dipotassium Phase 4
25 Folate Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
26 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
27
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
28
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
29
Ofloxacin Approved Phase 3 82419-36-1 4583
30
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
31
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
32
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
33
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
34
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
35
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 55-98-1 2478
36
Etoposide Approved Phase 2, Phase 3, Phase 1, Early Phase 1 33419-42-0 36462
37
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
38
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
39 Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
40
Lenalidomide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 191732-72-6 216326
41
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
42
Panobinostat Approved, Investigational Phase 2, Phase 3, Phase 1 404950-80-7 6918837
43
Piperacillin Approved Phase 3 66258-76-2 43672
44
Tazobactam Approved Phase 3 89786-04-9 123630
45
Vancomycin Approved Phase 3 1404-90-6 441141 14969
46
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
47
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
48
Dalteparin Approved Phase 3 9005-49-6
49
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
50
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965

Interventional clinical trials:

(show top 50) (show all 483)

id Name Status NCT ID Phase Drugs
1 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
2 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
3 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
4 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
5 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
6 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
7 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
8 PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
9 Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study Withdrawn NCT01801670 Phase 4
10 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
11 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
12 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
13 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
14 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Completed NCT00490776 Phase 2, Phase 3 LBH589
15 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
16 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
17 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
18 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
19 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
20 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
21 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
22 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
23 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
24 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
25 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
26 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
27 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
28 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
29 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
30 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
31 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
32 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
33 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
34 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
35 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
36 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
37 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Recruiting NCT01871727 Phase 3 E7777
38 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Recruiting NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
39 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With Mycosis Fungoides (MF) Form of CTCL Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
40 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Active, not recruiting NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate or Bexarotene
41 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Active, not recruiting NCT01728805 Phase 3 Vorinostat
42 PUVA Maintenance Therapy in Mycosis Fungoides Active, not recruiting NCT01686594 Phase 3 8-methoxypsoralen
43 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
44 Lenalidomide Maintenance Post-debulking in Advanced CTCL Terminated NCT01098656 Phase 3 lenalidomide
45 Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
46 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
47 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
48 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
49 Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Unknown status NCT01132989 Phase 2 Lenalidomide
50 Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study Unknown status NCT00779896 Phase 1, Phase 2 Tazarotene

Search NIH Clinical Center for Cutaneous T Cell Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: lymphoma, t-cell, cutaneous

Genetic Tests for Cutaneous T Cell Lymphoma

Anatomical Context for Cutaneous T Cell Lymphoma

MalaCards organs/tissues related to Cutaneous T Cell Lymphoma:

39
T Cells, Bone, Bone Marrow, Skin, Liver, Lymph Node, Kidney

Publications for Cutaneous T Cell Lymphoma

Articles related to Cutaneous T Cell Lymphoma:

(show top 50) (show all 858)
id Title Authors Year
1
AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair. ( 28884410 )
2017
2
Syringotropic Mycosis Fungoides: A Rare Form of Cutaneous T-cell Lymphoma Enabling a Histopathologic "Sigh of Relief." ( 28692463 )
2017
3
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. ( 28103725 )
2017
4
CUTANEOUS T-CELL LYMPHOMA WITH LYMPH NODE METASTASIS IN AN ADULT ADDAX (ADDAX NASOMACULATUS). ( 28920800 )
2017
5
A positive randomised trial in cutaneous T-cell lymphoma. ( 28600131 )
2017
6
Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma. ( 28803489 )
2017
7
Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma. ( 28711152 )
2017
8
Cutaneous T-cell Lymphoma. ( 28802499 )
2017
9
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-cell Lymphoma. ( 28729399 )
2017
10
Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. ( 28853310 )
2017
11
Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. ( 28805086 )
2017
12
miR-155 expression in Primary Cutaneous T-Cell Lymphomas (CTCL). ( 26935979 )
2017
13
Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells. ( 27929746 )
2017
14
Oral bexarotene for post-transplant cutaneous T-cell lymphoma. ( 28748653 )
2017
15
Haematological cancer: Brentuximab vedotin - a new standard for cutaneous T-cell lymphoma. ( 28631737 )
2017
16
Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma. ( 28889405 )
2017
17
Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma. ( 28685851 )
2017
18
Characterization of a novel canine T-cell line established from a dog with cutaneous T-cell lymphoma. ( 28668559 )
2017
19
Increased Interleukin-19 Expression in Cutaneous T-Cell Lymphoma and Atopic Dermatitis. ( 28597022 )
2017
20
Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. ( 28625481 )
2017
21
Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma: reply from authors. ( 28889619 )
2017
22
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. ( 28600132 )
2017
23
Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. ( 28872191 )
2017
24
Image Gallery: Cutaneous T-cell lymphoma mimicking a gyrate erythema. ( 27206367 )
2016
25
Hydroa Vacciniforme-Like EBV-Positive Cutaneous T-Cell Lymphoma, First Report of 2 Cases in Ecuador. ( 26913846 )
2016
26
Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma. ( 27054291 )
2016
27
Cutaneous T-Cell Lymphoma. A hypothesis on disease pathophysiology involving deficiency in DNA repair. ( 27501224 )
2016
28
Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside. ( 27262707 )
2016
29
Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. ( 27422033 )
2016
30
Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma. ( 27181628 )
2016
31
Primary Cutaneous T Cell Lymphoma (Gamma Delta subtype). ( 28064300 )
2016
32
Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. ( 27717961 )
2016
33
Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma. ( 27821903 )
2016
34
Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/SAczary syndrome): Use in a community setting. ( 27637355 )
2016
35
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. ( 26738536 )
2016
36
Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. ( 26923912 )
2016
37
Cutaneous T-cell Lymphoma Metastatic to the Retina. ( 27012697 )
2016
38
75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma. ( 27741338 )
2016
39
The role of polymorphism of interleukin-2, -10, -13 and TNF-I+ genes in cutaneous T-cell lymphoma pathogenesis. ( 28035219 )
2016
40
The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma. ( 26802931 )
2016
41
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. ( 27935859 )
2016
42
Cutaneous T-Cell Lymphoma Misdiagnosed as Lipodermatosclerosis. ( 26914225 )
2016
43
Inactivation of RUNX3/p46 Promotes Cutaneous T-Cell Lymphoma. ( 27377697 )
2016
44
The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines. ( 27002643 )
2016
45
Intrahepatic Xenograft of Cutaneous T-Cell Lymphoma Cell Lines: A Useful Model for Rapid Biological and Therapeutic Evaluation. ( 27181405 )
2016
46
Latest insights into pathogenesis of mycosis fungoides/cutaneous T-cell lymphoma. ( 27982549 )
2016
47
Primary Cutaneous T-cell Lymphoma with Aberrant Expression of CD20. ( 27840885 )
2016
48
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. ( 27247757 )
2016
49
Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma. ( 27351221 )
2016
50
Pagetoid reticulosis (epitheliotropic cutaneous T-cell lymphoma) in an adult alpaca (Vicugna pacos). ( 27154316 )
2016

Variations for Cutaneous T Cell Lymphoma

Cosmic variations for Cutaneous T Cell Lymphoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM532 KRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,cutaneous T cell lymphoma c.38G>A p.G13D 5

Copy number variations for Cutaneous T Cell Lymphoma from CNVD:

7 (show all 49)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21732 1 16100000 20300000 Amplification Cutaneous T-cell lymphoma
2 25426 1 189000000 192100000 Deletion Cutaneous T-cell lymphoma
3 38869 10 105700000 111800000 Deletion Cutaneous T-cell lymphoma
4 39996 10 12300000 17300000 Deletion Cutaneous T-cell lymphoma
5 41377 10 17300000 19900000 Amplification Cutaneous T-cell lymphoma
6 42285 10 31400000 34500000 Deletion Cutaneous T-cell lymphoma
7 47113 10 89600000 92900000 Deletion PTEN Cutaneous T-cell lymphoma
8 61605 12 10000000 12600000 Deletion ETV6 Cutaneous T-cell lymphoma
9 71417 12 69800000 74100000 Deletion Cutaneous T-cell lymphoma
10 77639 13 46200000 48900000 Deletion RB1 Cutaneous T-cell lymphoma
11 83022 14 19100000 23600000 Deletion NDRG2 Cutaneous T-cell lymphoma
12 83023 14 19100000 23600000 Deletion ZNF219 Cutaneous T-cell lymphoma
13 97437 16 10300000 12500000 Deletion Cutaneous T-cell lymphoma
14 98274 16 16700000 20500000 Deletion Cutaneous T-cell lymphoma
15 107006 17 11200000 15900000 Deletion MAP2K4 Cutaneous T-cell lymphoma
16 108845 17 23200000 28800000 Amplification DHRS13 Cutaneous T-cell lymphoma
17 108846 17 23200000 28800000 Amplification ERAL1 Cutaneous T-cell lymphoma
18 108847 17 23200000 28800000 Amplification FLOT2 Cutaneous T-cell lymphoma
19 108848 17 23200000 28800000 Amplification PHF12 Cutaneous T-cell lymphoma
20 112029 17 37800000 41900000 Amplification Cutaneous T-cell lymphoma
21 116538 17 6800000 11200000 Deletion TP53 Cutaneous T-cell lymphoma
22 120627 18 2900000 7200000 Amplification Cutaneous T-cell lymphoma
23 123359 18 71300000 76117153 Deletion PARD6G Cutaneous T-cell lymphoma
24 133686 19 6900000 12600000 Deletion Cutaneous T-cell lymphoma
25 142291 2 221300000 224900000 Deletion Cutaneous T-cell lymphoma
26 152036 20 28400000 31500000 Amplification BCL2L1 Cutaneous T-cell lymphoma
27 162458 22 21800000 24300000 Amplification Cutaneous T-cell lymphoma
28 162461 22 21800000 24300000 Deletion Cutaneous T-cell lymphoma
29 171538 3 169200000 172500000 Amplification PRKCI Cutaneous T-cell lymphoma
30 180261 4 102500000 107900000 Amplification Cutaneous T-cell lymphoma
31 180582 4 107900000 114100000 Amplification Cutaneous T-cell lymphoma
32 181002 4 114100000 120600000 Amplification Cutaneous T-cell lymphoma
33 184833 4 182600000 187300000 Deletion Cutaneous T-cell lymphoma
34 186902 4 40900000 45600000 Deletion Cutaneous T-cell lymphoma
35 190065 4 82600000 84300000 Deletion Cutaneous T-cell lymphoma
36 203973 6 104800000 113900000 Deletion Cutaneous T-cell lymphoma
37 206027 6 135200000 139100000 Deletion Cutaneous T-cell lymphoma
38 211016 6 31900000 33600000 Deletion Cutaneous T-cell lymphoma
39 212690 6 40600000 45200000 Deletion VEGFA Cutaneous T-cell lymphoma
40 222425 7 15200000 19500000 Deletion Cutaneous T-cell lymphoma
41 225996 7 53900000 57400000 Amplification EGFR Cutaneous T-cell lymphoma
42 233736 8 127300000 131500000 Amplification MYC Cutaneous T-cell lymphoma
43 237881 8 27400000 29700000 Deletion Cutaneous T-cell lymphoma
44 238080 8 29700000 38500000 Deletion Cutaneous T-cell lymphoma
45 239603 8 39900000 43200000 Deletion Cutaneous T-cell lymphoma
46 243701 8 87200000 93500000 Amplification Cutaneous T-cell lymphoma
47 244139 8 93500000 99100000 Deletion Cutaneous T-cell lymphoma
48 249980 9 19900000 25500000 Deletion CDKN2A Cutaneous T-cell lymphoma
49 255727 9 83400000 86100000 Deletion Cutaneous T-cell lymphoma

Expression for Cutaneous T Cell Lymphoma

Search GEO for disease gene expression data for Cutaneous T Cell Lymphoma.

Pathways for Cutaneous T Cell Lymphoma

Pathways related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 34)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 CCR4 HDAC9 IFNA1 IFNG IL15 IL2
2
Show member pathways
13.49 IFNA1 IFNG IL15 IL2 IL2RA IL4
3
Show member pathways
13.35 CCR4 IL15 IL2 IL2RA IL4 IL7
4
Show member pathways
13.3 IFNA1 IFNG IL15 IL2 IL2RA IL4
5
Show member pathways
13.23 CCR4 IL15 IL2 IL2RA IL4 IL7
6
Show member pathways
12.79 IFNA1 IFNG IL15 IL2 IL2RA IL4
7
Show member pathways
12.73 IFNA1 IFNG IL15 IL2 IL2RA IL4
8
Show member pathways
12.72 IL15 IL2 IL2RA IL4 IL7
9 12.62 HDAC9 IFNA1 IL2 IL2RA IL4 IL7
10
Show member pathways
12.53 IFNG IL2 IL2RA IL4 TGFBR1
11 12.48 IFNA1 IFNG IL2 IL2RA IL4
12
Show member pathways
12.44 IFNA1 IFNG IL2 IL4
13 12.35 IL15 IL2 IL2RA TGFBR1
14
Show member pathways
12.06 IFNA1 IFNG IL15 IL2 IL4
15
Show member pathways
11.94 IFNA1 IFNG IL15 IL2 IL2RA IL4
16
Show member pathways
11.9 IFNG IL2 IL2RA IL4
17
Show member pathways
11.84 IFNG IL4 TGFBR1
18 11.82 IL2RA IL4 IL7
19 11.82 IFNA1 IFNG IL15 IL2 IL2RA
20 11.8 IFNG IL15 IL2 IL2RA IL4 IL7
21 11.73 IFNG IL2 IL4
22
Show member pathways
11.69 IFNG IL2 IL2RA IL4
23
Show member pathways
11.63 IL2 IL2RA IL4
24
Show member pathways
11.58 IFNG IL2 IL2RA
25 11.41 IFNG IL2 IL2RA IL4
26 11.34 IFNG IL15 IL2 IL2RA IL4 IL7
27
Show member pathways
11.31 IFNG IL15 IL2 IL2RA
28 11.19 IFNG IL2 IL2RA IL4
29 11.16 IFNG IL2 IL2RA
30 11.15 IL15 IL2 IL4 IL7
31 11.13 IFNG IL15 IL4 IL7
32 11.12 IFNG IL2 IL4
33 10.98 IL4 TGFBR1
34 10.5 IFNG IL15 IL2 IL4 IL7

GO Terms for Cutaneous T Cell Lymphoma

Cellular components related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CCR4 IFNG IL2RA IL4

Biological processes related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.95 CCR4 HDAC9 IL15 IL2RA TNFRSF8
2 positive regulation of cell proliferation GO:0008284 9.91 IFNG IL15 IL2 IL4 IL7 TGFBR1
3 immune response GO:0006955 9.76 CCR4 IFNG IL15 IL2 IL2RA IL4
4 B cell differentiation GO:0030183 9.75 HDAC9 IFNA1 IL4
5 humoral immune response GO:0006959 9.71 IFNA1 IFNG IL7
6 positive regulation of B cell proliferation GO:0030890 9.67 IL2 IL4 IL7
7 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.63 IL4 IL7 TGFBR1
8 positive regulation of interleukin-17 production GO:0032740 9.59 IL15 IL2
9 positive regulation of chemokine biosynthetic process GO:0045080 9.58 IFNG IL4
10 regulation of defense response to virus by host GO:0050691 9.57 IFNG IL15
11 positive regulation of MHC class II biosynthetic process GO:0045348 9.56 IFNG IL4
12 positive regulation of activated T cell proliferation GO:0042104 9.54 IL2 IL2RA IL4
13 negative regulation of lymphocyte proliferation GO:0050672 9.52 IL2 IL2RA
14 positive regulation of tissue remodeling GO:0034105 9.51 IL15 IL2
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 IFNG IL2 IL4
16 negative regulation of T-helper 17 cell differentiation GO:2000320 9.48 IL2 IL4
17 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 IFNG IL2 IL4
18 regulation of T cell homeostatic proliferation GO:0046013 9.4 IL2 IL2RA
19 positive regulation of T cell proliferation GO:0042102 9.35 IFNG IL15 IL2 IL2RA IL4
20 positive regulation of T cell differentiation GO:0045582 8.92 IL2 IL2RA IL4 IL7

Molecular functions related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 IFNA1 IFNG IL15 IL2 IL4 IL7
2 cytokine receptor binding GO:0005126 8.92 IFNA1 IL15 IL4 IL7

Sources for Cutaneous T Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....